- Home
- NE vs AKRO Comparison
NE vs AKRO Comparison
Compare NE & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NE | AKRO |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NE | AKRO |
|---|---|---|
| Price | $29.77 | $54.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $32.67 | ★ $73.56 |
| AVG Volume (30 Days) | 1.7M | ★ 2.4M |
| Earning Date | 10-27-2025 | 11-07-2025 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $3,283,999,000.00 | N/A |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.19 | ★ N/A |
| Revenue Growth | ★ 24.12 | N/A |
| 52 Week Low | $17.40 | $21.34 |
| 52 Week High | $35.06 | $58.40 |
Technical Indicators
Market Signals| Indicator | NE | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 68.63 |
| Support Level | $30.73 | $54.30 |
| Resistance Level | $32.56 | $54.70 |
| Average True Range (ATR) | 1.16 | 0.17 |
| MACD | -0.25 | -0.10 |
| Stochastic Oscillator | 12.67 | 71.07 |
Price Performance
Historical ComparisonAbout NE Noble Corporation plc A
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.